Ocugen Advances Gene Therapy Licenses, Secures Korea Deal

Ocugen is making significant advancements in its gene therapy platform, with active Phase III recruitment for OCU400 in the U.S. and Canada and FDA approval for OCU410ST, positioning the company for regulatory filings in 2026. The company recently secured an exclusive licensing deal for OCU400 in Korea, which includes upfront payments, milestone fees, and a 25% royalty on net sales, enhancing its international market presence. Financially, Ocugen reported a second-quarter revenue of $1.37 million, nearly quadrupling analyst expectations, though it remains unprofitable with a net loss of $14.74 million. Despite ongoing losses, Ocugen's shares have risen about 28% year-to-date, supported by unanimous 'buy' analyst ratings and a median price target around $7.00, indicating strong investor confidence in its pipeline and business strategy. The company plans a reverse merger with OrthoCellix to expand into regenerative cell therapy, reflecting broader biotech trends toward innovative treatments and global partnerships. Overall, Ocugen's strategic clinical progress, licensing agreements, and favorable analyst outlook suggest promising growth potential in the competitive biotech sector.